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Abstract. Impaired cognitive function associatedwith use of anticholinergic drugsmay be partly attributed to underlying physical
illness and exposure to factors that increase the risk of some physical disorders such as low socioeconomic status (SES) and less
education. To estimate the extent of cognitive impairment and risk of progress to dementia associated with anticholinergic drug
use and to estimate confounding by gender, APOE, family history of dementia, lower SES, less education, and lower childhood
mental ability, we recruited 281 volunteers at age 77-78 without overt dementia who had taken part in the Scottish Mental
Survey of 1932. Clinical histories, use of medications, self reported frequency of emotional symptoms and standardized tests of
cognitive function were obtained. With and without adjustment for age and childhood IQ, there were signiﬁcant between-group
differences in tests of non-verbal reasoning and spatial ability. During 10 year follow-up, progress to overt dementia was not
associated with anticholinergic drugs use on recruitment but female gender and a history of dementia in parent or sibling were
associated with dementia. We concluded that anticholinergic drug use in this narrow age range sample was linked to cognitive
impairment but not to subsequent dementia.
Keywords: Aberdeen 1921 birth cohort, aging, anticholinergic, APOE, childhood intelligence, cognitive function, dementia,
drug, family history
∗Correspondence to: Dr. L.J. Whalley, MD, The Institute of
Applied Health Sciences, Foresterhill, University of Aberdeen,
Aberdeen AB25 2ZH Scotland, UK. Tel.: +441314469159;
E-mail: l.j.whalley@abdn.ac.uk.
INTRODUCTION
Anticholinergic drugs are associated with adverse
physical and cognitive effects in later life [1, 2].
These drugs are used to treat conditions as diverse as
bladder over activity [3, 4] and depressive disorders
[5]. Adverse effects of these drugs range from mild
ISSN 1387-2877/12/$27.50 © 2012 – IOS Press and the authors. All rights reserved
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impairment of recent memory to severe acute con-
fusional states [6, 7] and are mediated through brain
nicotinic receptors [8]. Cognitively impaired old peo-
ple with or without dementia in whom high afﬁnity
nicotinic receptors are already depleted [9–12] could,
therefore, be more susceptible to further cognitive
impairment when exposed to anticholinergic drugs
[13, 14].
With increasing age, exposures to physical and psy-
chiatric treatments increase. Although study samples,
measures of cognition, and classiﬁcation of anti-
cholinergic drugs have differed between studies, the
general view is that anticholinergic effects contribute
to cognitive impairment in older people [15–19]. This
conclusion, however, may not be secure for several
reasons. First, there could be other sources of individ-
ual differences in cognitive aging not considered (e.g.,
apolipoprotein E genotype [20]). Second, when cog-
nitive impairment is reported, it is generally uncertain
if this is attributable to increasing age (with associated
increased exposure to anticholinergic treatment), con-
comitant physical illness, or to the drugs themselves.
Third, while the value of serum anticholinergic activ-
ity remains undecided [21–24], most studies rely upon
self-report or prescribing records. Fourth, the choice of
cognitive tests has sometimes been constrained so that
when cognitive impairment attributable to anticholin-
ergic drugs is reported, it was uncertain if all or only
some cognitive domains are affected.
With one exception [19], published studies on anti-
cholinergic drug use in the absence of severe mental
disorder have examined subjects over the age of
65 years. We recognized that anticholinergic drugs
are often used in later life when concerns about
greater than expected cognitive aging arise. This line
of reasoning prompted us to consider the possibil-
ity that lower performance on cognitive tests taken
by older adults may reﬂect life-long lower cogni-
tive performance, lower socioeconomic status (SES),
less education, and gender differences and that these
attributes could also plausibly be linked to greater
morbidity of both physical and depressive disorders
[25–27]; the samedisorders that prompted introduction
of medications in later life including anticholinergic
drugs [28].
The ﬁrst aimof the studywas to identify associations
between domains of cognitive functioning and expo-
sure to anticholinergic drugs in a population-based
sample in good general health. The second aim was
to estimate the size of effect (if any) remaining after
adjustment for confounding by childhood mental abil-
ity, education, SES, andgender.And, third,we aimed to
investigate a possible association between anticholin-
ergic drug use and progress to dementia.
MATERIALS AND METHODS
Study design
We conducted a longitudinal observational study of
a narrow age range sample living independently in the
community and who were not known to be demen-
tia sufferers by local health agencies. We conducted
repeated clinical and neuropsychological assessments
at intervals of about 15 months after recruitment at
age 78 up to ages about 83 years in as many partici-
pants who remained available to study and who would
agree to re-assessment (Fig. 1). Final dementia diag-
noses were agreed by consensus between three authors
(LW, RS, AM) who had available all study data and in
subsets of the original sample relevant clinical records
and the ﬁndings of brain MRI, CT or SPECT.
Samples
In 1932, the Scottish Council for Research in Educa-
tion (SCRE) surveyed the mental ability (intelligence,
Fig. 1. Recruitment and retention of a sample of 281 volunteers all
born in 1921 and who took part in the 1932 Scottish Mental Survey
and who agreed in 1998–1999 to enter a prospective longitudinal
study of brain aging and health. The study was designed to retain
200 volunteers in the 1st and 2nd wave of the study. Aberdeen City
lies within the Grampian Region of Scotland where some of the
eligible participants now live.
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IQ) of the whole population of children born in
1921 [29]. More than 95% of eligible children were
included. Permission to trace local survivors with
archived intelligence test scores was given by SCRE
to the University of Aberdeen in 1997 to allow exact
matching by name and date of birth schoolchildren
who had remained in the Aberdeen area and were
listed on the local health register (more than 99% of
the population are registered). With the approval of
the Local Research Ethics Committee, we approached
local family doctors, who wrote to their patients who
hadparticipated in the 1932 survey andwere not known
to be in treatment for amajor illness, to havemajor sen-
sory impairment, or to have recently been bereaved.We
traced 354 individuals who had taken part in the 1932
survey and found 324 to be eligible. All were living
independently in the local community and were then
about 77 years old. In response to a postal invitation,
295 born in 1921 (88%) agreed to attend the Univer-
sity Clinical Research Unit to take part in a study of
brain aging and health of whom 14 declined to take
part after hearing more about the study (Fig. 1). On
attending, written informed consent to the study pro-
cedures was obtained by a trained research nurse from
281 volunteers.
Measures
Participants knew they could withdraw from all or
part of the study at anytime and some declined to
complete all cognitive tests. Data were obtained at
interview from all 281 participants about social back-
ground, education and occupational history, medical
and obstetric history, and family history of dementia.
A subsample of 98 individuals entered a longitudi-
nal study of brain MRI changes and survival [30] and
47 others underwent brain CT (n= 4), MRI (n= 9), or
SPECT (n= 34) for investigation of suspected demen-
tia from 1997 to 2010. Contact with participants was
maintained to 2010 through repeat clinical assess-
ments, home visits, cohort reunions and telephone
enquiries. For the present study, selected items were
taken from the complete research database to provide
information about exposure to possible anticholinergic
drugs. APOE4 status (4 present/absent) was deter-
mined in 225 participants using methods previously
described in this sample [31].
Follow-up assessments
Participants were invited to return for re-assessment
at intervals of about 15 months from age 77 to 83 years
(to a maximum of 5 assessments). At re-assessment,
the study protocol was repeated and included the same
questions about social circumstances, clinical history,
history of dementia in a parent or sibling, exposure to
drugs and repeat cognitive testing.
Dementia
Dementia diagnoses were based on ICD-10 crite-
ria [32] using data from research assessments, mental
testing, clinical records of contacts with treatment ser-
vices, results of brain imaging examinations (SPECT,
CT, or MRI), and telephone enquiries among fam-
ily and managers of residential care facilities. Brain
images were scrutinized by a specialist neuroradiolo-
gist (AM). At recruitment in 1998–2000, 24 volunteers
were found to be cognitively impaired (Mini-Mental
Status Examination (MMSE) <24) [33] and during
follow-up to 2010, all 24 subsequently met crite-
ria for Alzheimer’s disease (13 cases) or vascular
dementia with or without Alzheimer’s disease (11
cases). Clinical dementia diagnoses were established
by consensus between three authors (RS, AM, LW).
During follow-up from 1998 to 2010, 46 volunteers
who had scored >23 on the MMSE [33] on recruit-
ment developed dementia. The cumulative total of 70
dementia cases from age 77–88 years among 281 vol-
unteers recruited to the study comprised 24 possible
(MMSE<24) but unrecognized cases on recruitment
and 46 incident cases arising during follow up. Refusal
to take part was signiﬁcantly associated with lower
Moray House test (MHT) scores (p< 0.05). SES was
classiﬁed by usual occupation [34] and using the
Carstairs-Morris deprivation index [35] which is an
ecological measure of SES derived using small area
geographical parameters obtained from the 1991 Cen-
sus. This method of socioeconomic classiﬁcation does
not rely on a participant’s or spouse’s occupation and,
therefore, has some advantages for women, over clas-
siﬁcation by husband’s occupation.
Interview and cognitive measures
At interview with a trained research nurse, vol-
unteers provided detailed medical histories, family
history of dementia or stroke, accounts of numbers
of current prescribed and non-prescribed medications,
and completed tests of cognitive function supervised
by one of us (HF). A standardized brief cognitive
screening instrument, the MMSE [36], was used as
a practical method for detecting signiﬁcant cognitive
pathology. Volunteers undertook ﬁve cognitive tests:
256 L.J. Whalley et al. / Anticholinergic Drugs in Late Life
Raven’s Standardized Progressive Matrices [37], a
test of non-verbal reasoning; the Rey Auditory Ver-
bal Learning Test [38], which measures memory and
learning; and the Block Design subtest of the Wech-
sler Adult Intelligence Scale-Revised WAIS-R [39]
measuring spatial ability. Emotional symptoms were
recorded as self-reported scores on anxiety and depres-
sion subscales of the Hospital Anxiety and Depression
Scale [40].
Anticholinergic drugs
We calculated an anticholinergic burden of each
self-reported drug by reviewing relevant literature
associating known anticholinergic drugs with their
serum anticholinergic activity [17, 23]. Because there
are large differences between andwithin European and
North American clinical practices when prescribing
anticholinergic drugs, exact comparisons between this
and earlier studies are not possible. Each participant’s
interview accounts of current medications (obtained
on recruitment and at re-assessments) were indepen-
dently scrutinized by two of us (SS and LW) to classify
the anticholinergic burden from 0 to 3 (0 = no drugs
used, 1 = drugs used but with no likely effect, 2 = drugs
used with low effect, 3 = drugs used with high effect).
Duration of exposure to speciﬁc prescribed drugs was
estimated by direct questions. Volunteers were clas-
siﬁed as “regular” users of anticholinergics if one of
these drugs had been taken most days over the past
three months. Differences between scrutineers were
reconciled at joint review. We identiﬁed 15 anticholin-
ergic drugs common to this study and that reported by
Ancelin et al. [17]; 12 other drugs were identiﬁed only
in the Ancelin study and 35 other drugs were identiﬁed
only in this study.
Statistical methods
With the exception of MMSE, data approximated
to normal distribution and parametric statistics were
used throughout. Associations between cognitive test
scores and possible confounders were tested using
Pearson’s correlation coefﬁcient. Using data obtained
at recruitment, the effects of anticholinergic drugswere
examined by general linear modeling (multivariate
analysis of variance but excluding MMSE) with anti-
cholinergic drug exposure, gender, as ﬁxed effects, and
socioeconomic status, number of prescribed drugs and
childhood verbalmental ability as covariates. Repeated
measures of cognitive performance were examined in
a repeated measures mixed model using data provided
only by those participants who completed all ﬁve
assessments. The prediction of progress to dementia by
anticholinergic drug usewas examined by binary logis-
tic regression that included other possible risk factors
for dementia. These included female gender, family
history of dementia, APOE4 carrier status, childhood
IQ, history of heart disease, or treated hypertension.
RESULTS
The sample is described in Fig. 1 and Table 1 where
demographic characteristics are summarized for the
complete sample (n= 281) grouped by exposure to
no prescribed drugs, prescribed drugs but none with
anticholinergic effects and those exposed to anticholin-
ergics sub-grouped as “mild/moderate” or “strong”.
We identiﬁed seven participants who were taking
antidepressants and 20 who were taking a statin. These
groups were too small for separate analysis and their
distributions did not differ between subjects classiﬁed
by exposure to anticholinergic drugs. We recognized
that exposure to antidepressant drugs would be associ-
ated with a greater frequency of depressive symptoms
and that these might impair performance on cognitive
tests. Figure 2 shows the distribution of depressive
symptoms and numbers of volunteers who met cri-
teria for “caseness” for a depressive disorder. These
distributions did not differ signiﬁcantly between vol-
unteers grouped by exposure to anticholinergic drugs.
We examined the occurrence of exposure to prescribed
and non-prescribed anti-inﬂammatory drugs, but this
could not be quantiﬁed reliably largely because their
use was very often limited to the winter months. There
were signiﬁcant differences between sub-groups clas-
siﬁed by anticholinergic drug status in age at testing
(p= 0.015) and history of heart disease (p= 0.000) or
treated hypertension (p= 0.000). Demographic vari-
ables (gender, occupational classiﬁcation, deprivation
index by area of residence, duration of education,
childhood mental ability, smoking history, or MMSE
score) did not differ between groups.
Among 281 subjects recruited to the study, com-
plete sets of cognitive data were provided by 136
participants. These data comprised scores on Raven’s
Progressive Matrices, Auditory Verbal Learning, and
Block Design Tests (Table 2). Univariate analysis
of variance (Table 2) showed that Raven’s Progres-
sive Matrices, Block design, and MMSE scores were
signiﬁcantly lower in those exposed to “strong” anti-
cholinergics. Auditory Verbal Learning Test scores did
not distinguish between groups.
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Table 1
Sample characteristics grouped by exposure to no drugs, prescribed drugs – not anticholinergic, mild-moderate or strong anticholinergic drugs.
Values are means (standard deviation) or median (range). *Non-parametric test after combining mild/moderate and strong anticholinergic drugs.
**1 – most afﬂuent, 6 – most deprived
Not exposed to anticholinergic drugs Exposed to anticholinergic drugs Probability
no drugs prescribed drugs mild-moderate strong
n 84 118 66 13
Male/female 55/29 66/52 35/31 6/7 χ2 = 3.53, df = 3, p= 0.317
Age (years) 77.4 (1.0) 77.0 (0.7) 77.1 (0.6) 77.0 (0.6) F = 3.57, df = 3, p= 0.015
Occupation
Prof/admin 20 21 18 3 χ2 = 5.18, df = 4, p= 0.270*
Skilled manual 41 65 27 6
Unskilled manual 23 32 21 4
Deprivation (1–6**) 2.9 (1.3) 3.3 (1.4) 3.3 (1.3) 2.7 (1.1) F = 3.70, df = 3, p= 0.111
Education years median (range) 9.0 (7∼17) 9.7 (8∼16) 9.6 (8∼18) 9.0 (9∼16) KW, df = 3, p= 0.548
IQ age 11 yrs 101.1 (14.4) 102.1 (14.6) 101.0 (13.6) 106.0 (10.3) F = 0.479, df = 3, p= 0.687
Incident dementia 15 18 10 2 χ2 = 0.424, df = 3, p= 0.81*
Family history dementia 10 25 13 3 χ2 = 3.52, df = 3, p= 0.17*
History heart disease 6 33 35 7 χ2 = 42.11, df = 3, p= 0.000
History hypertension 3 58 17 6 χ2 = 50.80, df = 3, p= 0.000
Smoking history
Never smoked 19 33 14 5
Ex-smoker 34 52 37 5 χ2 = 6.244, df = 6, p= 0.396
Current smoker 5 16 4 2
Alcohol (units/week)
None 54 64 30 4 χ2 = 6.820, df = 6, p= 0.338*
1–4 11 17 12 3
5–14 14 23 15 5
>14 5 14 9 1
Multivariate analyses of cognitive test data with
adjustment for age and childhood IQ showed differ-
ences between groups; Pillai’s Trace = 0.140, F = 2.02,
df 9,372, p= 0.036. These differences were located
to the group using “strong” anticholinergics” in
lower Raven’s Progressive Matrices scores (F = 3.70,
p= 0.013, η2 = 0.06) and Block Design (F = 3.53,
p= 0.017, η2 = 0.08). Auditory Verbal Learning Test
scores did not differ between groups (F = 0.26,
p= 0.852, η2 = 0.006).
Binary Logistic regression was used to examine pre-
diction of progress to dementia. Two regressionmodels
were examined (Table 3). InModel 1 (n= 257), demen-
tia predictionwas tested in 257 subjects after exclusion
of those who had scored <24 on the MMSE. In Model
2, dementia prediction was tested in 210 subjects after
exclusion of those who had not agreed to blood sam-
pling for APOE genotyping.
DISCUSSION
Our aims were to examine associations between
exposure to anticholinergic drugs and cognitive per-
formance with and without adjustment for likely
confounders. Many studies [1, 2, 15–19] report
that anticholinergic medications produce cognitive
impairments in the elderly. Without adjustment for
covariables, in two non-clinical cohorts of inde-
pendent, community dwelling volunteers, we found
signiﬁcantly lower cognitive scores in those using
anticholinergic drugs. Speciﬁcally, scores on tests of
verbal reasoning (Raven’s Progressive Matrices) and
spatial ability (Block Design) were signiﬁcantly worse
in participants who reported taking “relatively strong”
anticholinergic. After adjustment for covariables (age
on recruitment and childhood mental ability) in a mul-
tivariate analysis, the results of the univariate analysis
were supported. In logistic regression analyses of pre-
diction of progress to late onset dementia, inclusion of
use of anticholinergic drugs as an additional predictor
did not improve prediction beyond that provided by
gender, age and a history of dementia in a parent or
sibling.
The main strength of the study is that our subjects
were non-clinical volunteers living independently in
the community. Their cognitive functions were not
compromised by intercurrent physical disorders suf-
ﬁcient to impair their ability to live independently in
the community. Within the total study sample, there
were small subgroups with long-term exposure to
drugs (e.g., non-steroidal inﬂammatory agents) that
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Fig. 2. Hospital Anxiety and Depression Scale (HADS) depressive symptom scores in 281 community residents without dementia classiﬁed
by exposure to prescribed medicines (no medications, not anticholinergic and possible/deﬁnite anticholinergic drug). The broken vertical line
is drawn at HADS= 8, a conventional cut-off for case recognition of depressive disorder [41].
Table 2
Cognitive test scores in 136 volunteers without dementia grouped by exposure to anticholinergic drugs. Values are means (standard deviation)
Not exposed to anticholinergic Exposed to anticholinergic Probability df 3,129
No drugs Prescribed drugs Mild-moderate Strong
n= 39 n= 59 n= 30 n= 8
Raven’s progressive matrices 30.8 (9.4) 28.6 (8.3) 30.6 (8.5) 21.6 (7.1) F = 2.89, p= 0.038
Block design 20.1 (6.9) 20.5 (7.2) 18.5 (7.3) 12.6 (5.8) F = 3.22, p= 0.025
Auditory verbal learning test 47.6 (14.1) 48.6 (12.5) 48.8 (12.0) 44.5 (9.9) F = 0.28, p= 0.838
Mini-mental state examination 28.6 (1.9) 28.1 (2.3) 28.2 (1.4) 26.8 (3.7) Kruskal-Wallis, p= 0.021
may have modiﬁed their dementia risk. These groups
were too small to merit separate analysis but in a larger
study such subgroups may provide valuable insights
into the modiﬁcation of dementia risk by use of med-
ications. Additional strengths were identiﬁcation of
other factors that could potentially explain some of the
observed impairment of cognitive function. The main
limitation of the studywas that we did not exactlymea-
sure the anticholinergic load using serum assays and
biologicalmarkers of anticholinergic effectswere lack-
ing. However, our review and classiﬁcation of possible
anticholinergic drugs is probably relevant to current
clinical practice in the United Kingdom. We based our
review on studies which had determined anticholin-
ergic activity directly from blood concentrations of
anticholinergic drugs and their binding to cholinergic
receptors. There are also international differences in
the type of anticholinergic drugs prescribed. This point
is emphasized when prescribed drugs are compared
between this and the Ancelin study [17].
Our ﬁndings are relevant to therapeutic studies and
epidemiological studies of cognitive aging and demen-
tia incidence. From our data, it appears prudent to
include self-reports of use of anticholinergic drugs as
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Table 3
Binary logistic regression models of prediction of progression to dementia before age 88 in subjects without dementia at age 78 after exclusion
of 24 subjects who scored <24 on MMSE at recruitment. Model 2 (n= 210) includes APOE4 genotypic data that were unavailable for model
1 analysis (n= 257). IQ – intelligence quotient at age 11; FHxDem – history of dementia in a parent or sibling; Heart Hx – personal history of
treated heart disease; BP Hx – personal history of treated hypertension; Antichol – exposed to anticholinergic drugs (mild-moderate-strong);
APOE – apolipoprotein E; CI conﬁdence intervals: lower∼upper
Predictor Model 1 (n= 257) Hosmer and Lemeshow Model 2 (n= 210) Hosmer and Lemeshow
χ2 = 12.78, df 8, p= 0.12 χ2 = 7.07, df 8, p= 0.53
 S.E. probability exp  95% CI. exp   S.E. probability exp  95% CI. exp 
Female gender 1.243 0.442 0.005 3.46 1.46∼8.25 1.257 0.445 0.005 3.52 1.47∼8.40
IQ age 11 0.006 0.015 0.67 1.01 0.98∼1.04 0.01 0.015 0.619 1.00 0.98∼1.04
Age −0.959 0.43 0.026 0.38 0.17∼0.89 −0.961 0.43 0.026 0.38 0.17∼0.89
FhxDem 1.757 0.447 0.000 5.8 2.42∼13.91 1.77 0.448 0.000 5.89 2.45∼14.17
Education −0.102 0.119 0.394 0.9 0.72∼1.14 −0.1 0.119 0.381 0.9 0.71∼1.14
Heart Hx 0.373 0.466 0.424 1.45 0.58∼3.62 0.346 0.47 0.462 1.41 0.56∼3.56
BP Hx −0.219 0.451 0.627 0.8 0.33∼1.95 −0.261 0.46 0.571 0.77 0.31∼1.90
Antichol −0.416 0.269 0.121 0.66 0.39∼1.12 −0.396 0.272 0.146 0.67 0.40∼1.15
APOE ε4 – – – – 0.214 0.439 0.626 1.24 0.52∼2.93
potential confounders in the study of individual dif-
ferences in rates of cognitive aging. These data do
not, however, suggest that anticholinergic drug use
contributes to the risk of progression to dementia.
In models 1 and 2, some established dementia risk
factors were found to be associated with dementia
(female gender and a history of dementia in a par-
ent or sibling) while use of anticholinergics was not.
The observation that increased age at recruitment is
linked to reduced dementia risk is possibly an artifact
of sampling.
Comparisons between these results and earlier
reports suggest some similarities: we found spatial
ability was signiﬁcantly worse in anticholinergic drug
users as did Ancelin et al. [17] in a larger study than
reported here. However, it striking that in our sam-
ple of relatively healthy volunteers we failed to obtain
agreement for complete neuropsychological testing in
almost 50% of those recruited whereas Ancelin et al.
[17] achieved 100% compliance in a comparable sam-
ple also recruited fromgeneral practice andwhen using
more demanding cognitive and psychophysiological
tests. As in the present study, Ancelin et al. [17] did
not ﬁnd an association between anticholinergic drug
use and progress to dementia. Comparisons between
this and earlier studies show that we were unable to
support associations between anticholinergic drug use
and lower verbal memory scores [15] or deﬁcits in
attention [19] but lower scores on the MMSE found
here are similar to reports elsewhere suggesting lower
general cognitive ability is associated with anticholin-
ergic drug use [42, 43]. In the largest study to date
of this type, Campbell et al. [44] found that regular
use of anticholinergics was associated with general
cognitive impairment ascertained by either worse
performance on tests of general mental ability or
progress to dementia.
We conclude that use of anticholinergic drugs is
associated with lower scores on tests of cognitive
ability and that consistentwith other studies, this is sup-
ported byworse performance on tests of general ability
and, spatial ability which may be selectively affected
by anticholinergics. In our multivariate model, we
found that anticholinergic drug use possibly accounted
for 6–8% of the variability among old people in scores
on non-verbal reasoning and spatial ability. Like oth-
ers [17], we did not ﬁnd a link between anticholinergic
drug use and progress to dementia.
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